Fintel reports that on April 21, 2025, Wolfe Research upgraded their outlook for Walt Disney (SNSE:DISCL) from Peer Perform to Outperform. There are 4,576 funds or institutions reporting positions ...

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research Report), with a price target of $4.00. The company’s ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation ...

Get the next trade alert free. Sensei Biotherapeutics Inc. SNSE late Thursday released initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug (formerly SNS ...

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation ...

Fintel reports that on April 21, 2025, Wolfe Research upgraded their outlook for Walt Disney (SNSE:DIS) from Peer Perform to Outperform. There are 4,576 funds or institutions reporting positions ...